izpis_h1_title_alt

Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase : a new approach for the treatment of Alzheimer's disease
ID Ferjančič Benetik, Svit (Author), ID Knez, Damijan (Author), ID Obreza, Aleš (Author), ID Košak, Urban (Author), ID Gobec, Stanislav (Author)

.pdfPDF - Presentation file, Download (623,74 KB)
MD5: D8D3AC04077BC139EE946151BA944B61
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0163725824001682 This link opens in a new window

Abstract
The simultaneous targeting of neuroinflammation and cholinergic hypofunction, the key pathological changes in Alzheimer's disease (AD), is not addressed by drugs currently in clinical trials, highlighting a critical therapeutic gap. We propose that dual-acting small molecules that inhibit butyrylcholinesterase (BChE) and mitogen-activated protein kinase p38α (p38α MAPK) represent a novel strategy to combat AD. This hypothesis is supported by cellular and animal studies as well as in silico modelling showing that it is possible to act simultaneously on both enzymes. Amyloid beta (Aβ) plaques trigger a pro-inflammatory microglial response that overactivates p38α MAPK, leading to increased Aβ synthesis, tau hyperphosphorylation, and altered synaptic plasticity. Overactivated microglia exacerbate neuroinflammation and cholinergic degeneration, ultimately leading to cognitive impairment. Structural similarities between the binding sites of BChE and p38α MAPK provide a promising basis for the development of dual inhibitors that could alleviate AD symptoms and address the underlying pathology.

Language:English
Keywords:Alzheimer's disease, neuroinflammation, butyrylcholinesterase, p38α mitogen-activated protein kinase, neurodegeneration, selectivity
Work type:Article
Typology:1.02 - Review Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:13 str.
Numbering:Vol. 264, art. 108748
PID:20.500.12556/RUL-164882 This link opens in a new window
UDC:616.894
ISSN on article:0163-7258
DOI:10.1016/j.pharmthera.2024.108748 This link opens in a new window
COBISS.SI-ID:215038723 This link opens in a new window
Publication date in RUL:15.11.2024
Views:60
Downloads:29
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmacology & therapeutics
Shortened title:Pharmacol. ther.
Publisher:Elsevier
ISSN:0163-7258
COBISS.SI-ID:26118144 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:Alzheimerjeva bolezen, nevrovnetje, butirilholinesteraza, p38α mitogen aktivirana protein kinaza, nevrodegeneracija, nevrodegenerativne bolezni

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:N1-0277
Name:Raziskave multifunkcionalnih spojin, usmerjenih proti nevroinflamaciji in holinergičnemu pomanjkanju pri Alzheimerjevi bolezni

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Young researchers

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back